133 related articles for article (PubMed ID: 1633400)
1. Diagnosis of fatty liver with MR imaging.
Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD
J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents.
Kreft BP; Tanimoto A; Baba Y; Zhao L; Finn JP; Stark DD
J Magn Reson Imaging; 1994; 4(3):337-42. PubMed ID: 8061431
[TBL] [Abstract][Full Text] [Related]
3. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
4. Liver-specific contrast agents for MRI.
Stark DD; Elizondo G; Fretz CJ
Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535
[No Abstract] [Full Text] [Related]
5. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of liver contrast agents: impact for clinical use.
Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.
Kim YK; Kim CS; Kwak HS; Lee JM
J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325
[TBL] [Abstract][Full Text] [Related]
8. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of superparamagnetic iron oxide for MR imaging of liver injury: proton relaxation mechanisms and optimal MR imaging parameters.
Tanimoto A; Mukai M; Kuribayashi S
Magn Reson Med Sci; 2006 Jul; 5(2):89-98. PubMed ID: 17008765
[TBL] [Abstract][Full Text] [Related]
10. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
[TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced MR imaging of the liver.
Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis.
Tanimoto A; Kreft BP; Baba Y; Zhao L; Finn JP; Compton CC; Stark DD
J Magn Reson Imaging; 1993; 3(5):786-93. PubMed ID: 8400566
[TBL] [Abstract][Full Text] [Related]
13. Liver-specific MR imaging contrast agents.
Hahn PF; Saini S
Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
[TBL] [Abstract][Full Text] [Related]
14. Ex-vivo MR imaging of liver intracellular contrast agents.
Mascalchi M; Jin XN; Agen C; Petruzzi P; Nardini D; Tessa C; Caramella D; Bartolozzi C
Magn Reson Imaging; 1997; 15(4):469-74. PubMed ID: 9223047
[TBL] [Abstract][Full Text] [Related]
15. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
[TBL] [Abstract][Full Text] [Related]
16. Nondiffuse fatty change of the liver: discerning pseudotumor on MR images enhanced with ferumoxides-initial observations.
Hirohashi S; Ueda K; Uchida H; Ono W; Takahama J; Takewa M; Kitano S; Ohishi H
Radiology; 2000 Nov; 217(2):415-20. PubMed ID: 11058637
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging of experimental inflammatory bowel disease: quantitative and qualitative analyses with histopathologic correlation in a rat model using the ultrasmall iron oxide SHU 555 C.
Frericks BB; Wacker F; Loddenkemper C; Valdeig S; Hotz B; Wolf KJ; Misselwitz B; Kühl A; Hoffmann JC
Invest Radiol; 2009 Jan; 44(1):23-30. PubMed ID: 18836385
[TBL] [Abstract][Full Text] [Related]
18. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents.
Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM
Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202
[TBL] [Abstract][Full Text] [Related]
19. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.
Marin D; Iannaccone R; Catalano C; Passariello R
J Magn Reson Imaging; 2006 Sep; 24(3):690-4. PubMed ID: 16878304
[TBL] [Abstract][Full Text] [Related]
20. Value of dual contrast liver MRI at 3.0 T in differentiating well-differentiated hepatocellular carcinomas from dysplastic nodules: preliminary results of multivariate analysis.
Yoon MA; Kim SH; Park HS; Lee DH; Lee JY; Han JK; Choi BI
Invest Radiol; 2009 Oct; 44(10):641-9. PubMed ID: 19724237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
